Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

11.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.3K
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

107
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
107
Cancer Prevention02:59

Cancer Prevention

6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.0K
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

3.1K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redox chemistry of early Earth and the origin of life.

Communications chemistry·2026
Same author

Cytochrome P450 monooxygenase systems: Diversity and plasticity for adaptive stress response.

Progress in biophysics and molecular biology·2024
Same author

Lipid peroxidation: Reactive carbonyl species, protein/DNA adducts, and signaling switches in oxidative stress and cancer.

Biochemical and biophysical research communications·2023
Same author

Evolutionary Conserved Short Linear Motifs Provide Insights into the Cellular Response to Stress.

Antioxidants (Basel, Switzerland)·2023
Same author

Short Linear Motifs Orchestrate Functioning of Human Proteins during Embryonic Development, Redox Regulation, and Cancer.

Metabolites·2022
Same author

Predictive biomarkers for systemic therapy of hepatocellular carcinoma.

Expert review of molecular diagnostics·2021

Related Experiment Video

Updated: Jun 4, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

624

Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review.

Innokenty M Mokhosoev1, Dmitry V Astakhov2, Alexander A Terentiev3

  • 1Independent Researcher, 108815 Moscow, Russia.

Cells
|December 17, 2024
PubMed
Summary

Cytochrome P450 (CYP) enzymes exhibit diverse metabolic activities, influencing both cancer development and drug response. Understanding CYP functions and genetic variations is crucial for personalized cancer therapies.

Keywords:
CYPsbioactivation vs. detoxificationdrugs as substrates, inducers, and inhibitorsgene polymorphismshormone-dependent cancersnuclear receptors and efflux transporters

More Related Videos

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

13.8K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K

Related Experiment Videos

Last Updated: Jun 4, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

624
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

13.8K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Cytochromes P450 (CYPs) are essential heme-containing oxidoreductases with broad mono-oxygenase activity.
  • Human CYPs metabolize a vast array of endogenous and exogenous compounds, including drugs, hormones, and procarcinogens.

Purpose of the Study:

  • To review recent findings on the dual role of CYP isoforms in bioactivation and detoxification.
  • To explore the involvement of CYPs in hormone-sensitive cancers and drug resistance.
  • To discuss the impact of CYP gene polymorphisms on cancer and drug susceptibility.

Main Methods:

  • Literature review of recent data on CYP functions and their implications in cancer.
  • Analysis of CYP involvement in hormone metabolism and cancer development (breast, ovarian, endometrial, prostate).
  • Examination of CYP-mediated drug metabolism, drug-drug interactions, and their role in anticancer drug resistance.

Main Results:

  • CYP isoforms can either activate or detoxify substrates, leading to varied toxicological outcomes depending on reaction type, substrate, tissue, and species.
  • CYP-mediated metabolism of estrogens and androgens is critical in hormone-sensitive cancers; specific CYP activities contribute to prostate cancer progression.
  • CYP gene polymorphisms influence individual susceptibility to cancer and drug efficacy, affecting metabolizer phenotypes.

Conclusions:

  • The metabolic versatility and dual biological effects of CYPs are central to their role in hormone-sensitive cancers.
  • Interindividual variability in cancer and drug susceptibility is linked to CYP activity variations and genetic polymorphisms.
  • CYP inhibitors represent a promising avenue for developing personalized anticancer therapies.